Você procurou por: eptotermin (Inglês - Maltês)

osigraft eptotermin alfa
osigraft eptotermin alfa

3.3 mg of eptotermin alfa
3.3 mg ta’ eptotermin alfa.

1 g (3.5 mg eptotermin alfa)
1 g (3. 5 mg ta’ eptotermin alfa)

1g powder (3.5 mg eptotermin alfa)
1g ta ’ trab (3. 5 mg ta ’ eptotermin alfa)

one vial containing 3.3 mg of eptotermin alfa
kunjett fih 3.3 mg ta’ eptotermin alfa.

each vial contains 3.3 mg eptotermin alfa*.
kull kunjett fih 3.3 mg eptotermin alfa*.

each vial contains 3.3 mg of eptotermin alfa*
kull kunjett fih 3.3 mg ta’ eptotermin alfa

powder (eptotermin alfa): vial (glass/ alu)
trab (eptotermin alfa): kunjett (ħġieġ/ alu) trab (carboxymethylcellulose): kunjett (ħġieġ/ alu)

when implanted, eptotermin alfa stimulates the formation of new bone.
meta tkun impjantata, eptotermina alfa tistimula l-formazzjoni ta’ għadam ġdid.

osigraft 3.3 mg powder for suspension for implantation eptotermin alfa
osigraft 3.3 mg, trab għal suspensjoni għall-impjantazzjoni eptotermin alfa

opgenra is a medicine that contains the active substance eptotermin alfa.
opgenra huwa mediċina li fiha s-sustanza attiva eptotermina alfa.

opgenra 3.5 mg powder for suspension for implantation eptotermin alfa intraosseous use
eptotermin alfa użu intraossejojuż

the replacement eptotermin alfa acts in the same way as naturally produced bmp-7.
l-eptotermina alfa sostituta taġixxi bl-istess mod bħal bmp-7 magħmul b’mod naturali.

2 x 1 vial containing 1 g of powder (3.3 mg eptotermin alfa).
2 x 1 kunjett li fih 1 g ta’ trab (3.3 mg eptotermin alfa).

- if you are allergic to eptotermin alfa or collagen, the other ingredient of osigraft.
- jekk int allerġiku/ a għall- eptotermin alfa jew kollaġen, l- ingredjent l- ieħor ta ’ osigraft.

when implanted, eptotermin alfa stimulates the formation of new bone, helping to repair the broken bone.
meta impjantata, l-eptotermina alfa tistimula l-formazzjoni ta’ għadam ġdid, b’hekk tgħin biex jissewwa l-għadam miksur.

it is supplied as two vials, one containing eptotermin alfa and another containing a substance called carmellose.
jiġi bħala żewġ kunjetti, wieħed li fih eptotermina alfa u ieħor li fih sustanza msejħa karmelloża (carmellose).

eptotermin alfa in freund’s adjuvant was first administered subcutaneously with booster doses given after 14 and 28 days.
eptotermin alfa fl-adjuvant ta’ freund ngħata l-ewwel taħt il-ġilda b’dożi booster li ngħataw wara 14 u 28-il ġurnata.

one vial containing 1g of powder (3.3 mg eptotermin alfa); one vial containing 230 mg carmellose powder.
kunjett wieħed li fih 1g ta’ trab (3.3 mg eptotermin alfa); kunjett wieħed li fih 230 mg trab carmellose.

therefore, upon re- administration of eptotermin alfa, a risk of developing autoimmunity towards the endogenous bmp proteins may exist.
mela, hekk kif jerġa’ jingħata eptotermin alfa, għandu mnejn ikun hemm riskju li tiżviluppa awtoimmunità lejn il-proteini bmp endoġenużi